VistaGen Therapeutics, Inc. logo VTGN - VistaGen Therapeutics, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 3
HOLD 4
SELL 0
STRONG
SELL 0
| PRICE TARGET: $0.95 DETAILS
HIGH: $1.00
LOW: $0.90
MEDIAN: $0.95
CONSENSUS: $0.95
UPSIDE: 64.87%

Stock News

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company's clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory.

Jun 09, 2026 04:30 AM • businesswire.com
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Vistagen Therapeutics caused the company to misrepresent or fail to disclose the risk of failure inherent in public speaking challenge-based Social Anxiety Disorder clinical trials.

Jun 01, 2026 10:40 AM • prnewswire.com (Hide legal announcements)
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team,” said President and Chief Executive Officer of Vista.

May 19, 2026 04:30 AM • businesswire.com
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time. The Company will also host.

May 14, 2026 04:30 AM • businesswire.com
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced preliminary positive data from the ongoing open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a recent analysis of subjects who el.

May 12, 2026 03:30 AM • businesswire.com
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company's Phase 3 clinical trial evaluating fasedienol nasal spray for the acute trea.

May 08, 2026 03:30 AM • businesswire.com
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop

SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Vistagen Therapeutics, Inc. (NASDAQ: VTGN) investors that the firm is investigating potential legal claims arising from alleged false statements about Vistagen's drug candidate fasedienol. Current shareholders are encouraged to contact the firm.

Apr 28, 2026 05:00 AM • prnewswire.com (Hide legal announcements)
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) under its U.S. Investigational New Drug (IND) application for refisolone nasal spray, the Company's non-hormonal, non-systemic.

Apr 22, 2026 04:30 AM • businesswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN). Such investors are advised to contact Danielle Peyton at  [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Mar 17, 2026 11:49 AM • globenewswire.com (Hide legal announcements)
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight

CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight

NEW YORK--(BUSINESS WIRE)---- $VTGN #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) and reminds investors of the March 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Mar 16, 2026 07:09 AM • businesswire.com (Hide legal announcements)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, March 16, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen" or "the Company") (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 1, 2024 and December 16, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before March 16, 2026.

Mar 16, 2026 01:00 AM • prnewswire.com (Hide legal announcements)
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, March 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. So what: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Mar 16, 2026 01:00 AM • prnewswire.com (Hide legal announcements)
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

LOS ANGELES, March 16, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen" or "the Company") (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Mar 15, 2026 10:38 PM • prnewswire.com (Hide legal announcements)

Price Targets